• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Panuveitis induced by brentuximab vedotin: a possible novel adverse event of an antibody-drug conjugate.

作者信息

Costa Philippos Apolinario, Espejo-Freire Andrea Patricia, Fan Kenneth Chen, Albini Thomas Arno, Pongas Georgios

机构信息

Department of Medicine, Division of Internal Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.

Department of Medicine, Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.

出版信息

Leuk Lymphoma. 2022 Jan;63(1):239-242. doi: 10.1080/10428194.2021.1978090. Epub 2021 Sep 13.

DOI:10.1080/10428194.2021.1978090
PMID:34514943
Abstract
摘要

相似文献

1
Panuveitis induced by brentuximab vedotin: a possible novel adverse event of an antibody-drug conjugate.本妥昔单抗引起的全葡萄膜炎：抗体药物偶联物一种可能的新型不良事件。
Leuk Lymphoma. 2022 Jan;63(1):239-242. doi: 10.1080/10428194.2021.1978090. Epub 2021 Sep 13.
2
Apoptotic colitis secondary to Brentuximab Vedotin: an immune mediated adverse event responsive to steroid treatment.维布妥昔单抗继发的凋亡性结肠炎：一种对类固醇治疗有反应的免疫介导不良事件。
Leuk Lymphoma. 2023 Jul-Aug;64(8):1497-1499. doi: 10.1080/10428194.2023.2220453. Epub 2023 Jun 6.
3
Brentuximab vedotin-induced pancreatitis in lymphoma: a pharmacovigilance study.本妥昔单抗致淋巴瘤患者胰腺炎：一项药物警戒研究。
Leuk Lymphoma. 2022 Jul;63(7):1768-1769. doi: 10.1080/10428194.2022.2045601. Epub 2022 Mar 6.
4
Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies.本妥昔单抗维达汀不会导致 CD30 阳性血液恶性肿瘤患者出现临床相关的 QTc 间期延长。
Cancer Chemother Pharmacol. 2013 Jul;72(1):241-9. doi: 10.1007/s00280-013-2192-z. Epub 2013 May 30.
5
Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies.在未经移植的复发或难治性霍奇金淋巴瘤患者中应用 Brentuximab vedotin：两项 I 期研究的分析。
Oncologist. 2012;17(8):1073-80. doi: 10.1634/theoncologist.2012-0133. Epub 2012 Aug 1.
6
Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma?本妥昔单抗维迪西妥单抗在霍奇金淋巴瘤患者的治疗管理中处于什么位置？
Curr Hematol Malig Rep. 2012 Sep;7(3):179-85. doi: 10.1007/s11899-012-0126-1.
7
A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.一项抗体药物偶联物 Brentuximab Vedotin 联合再诱导化疗治疗 CD30 表达的复发/难治性急性髓系白血病患者的 1 期研究。
Cancer. 2020 Mar 15;126(6):1264-1273. doi: 10.1002/cncr.32657. Epub 2019 Dec 20.
8
Single-agent brentuximab vedotin as frontline therapy for Hodgkin lymphoma patients with severe hepatic impairment: a report of two cases.单药本妥昔单抗作为严重肝功能损害的霍奇金淋巴瘤患者的一线治疗：两例报告
Ann Hematol. 2023 Oct;102(10):2973-2975. doi: 10.1007/s00277-023-05390-4. Epub 2023 Jul 31.
9
CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies.CYP3A 介导的药物-药物相互作用潜力以及 CD30 阳性血液系统恶性肿瘤患者中抗体药物偶联物 Brentuximab Vedotin 的排泄。
J Clin Pharmacol. 2013 Aug;53(8):866-77. doi: 10.1002/jcph.116. Epub 2013 Jun 10.
10
Severe Progressive Mycobacterium avium Complex Infection Associated With Brentuximab Vedotin Therapy.与维布妥昔单抗治疗相关的严重进行性鸟分枝杆菌复合群感染
J Pediatric Infect Dis Soc. 2019 Sep 25;8(4):371-373. doi: 10.1093/jpids/piy109.

引用本文的文献

1
Insights into uveitis from Brentuximab vedotin in refractory Hodgkin's lymphoma: a case report and brief review.从维布妥昔单抗治疗难治性霍奇金淋巴瘤中洞察葡萄膜炎：一例报告及简要综述
Front Oncol. 2024 Aug 5;14:1419145. doi: 10.3389/fonc.2024.1419145. eCollection 2024.
2
Ocular adverse events associated with antibody-drug conjugates for cancer: evidence and management strategies.与癌症抗体药物偶联物相关的眼部不良事件：证据和管理策略。
Oncologist. 2024 Nov 4;29(11):e1435-e1451. doi: 10.1093/oncolo/oyae177.
3
Cardiac toxicity of brentuximab vedotin: a real-word disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database.
贝林妥欧单抗的心脏毒性：FDA 不良事件报告系统（FAERS）数据库的真实世界比例失调分析。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Jul;397(7):5253-5264. doi: 10.1007/s00210-024-02955-6. Epub 2024 Jan 25.